Updated Jul 16, 2026
Anderson Karen M. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $9.93M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | CNTA | Centessa Pharmaceuticals plc | D — Derivative transaction | 62.1K | — | |
| 2026-03-27 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 41.1K | $30.12 | $1.24M |
| 2026-03-27 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 41.1K | $8.01 | $329K |
| 2026-03-18 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 10.0K | $28.10 | $282K |
| 2026-03-18 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 10.0K | $4.01 | $40K |
| 2026-03-18 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 64.8K | $28.21 | $1.83M |
| 2026-03-18 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 64.8K | $4.01 | $260K |
| 2026-03-16 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 12.1K | $27.13 | $327K |
| 2026-03-16 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 108.0K | $26.15 | $2.82M |
| 2026-03-16 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 15.2K | $3.85 | $58K |
| 2026-03-16 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 94.2K | $4.01 | $378K |
| 2026-03-13 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 12.1K | $27.13 | $327K |
| 2026-03-13 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 108.0K | $26.15 | $2.82M |
| 2026-03-13 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 109.4K | $4.01 | $439K |
| 2026-02-03 | CNTA | Centessa Pharmaceuticals plc | A — Grant or award | 29.0K | $0.00 | |
| 2026-02-03 | CNTA | Centessa Pharmaceuticals plc | F — Tax withholding / forfeiture | 10.6K | $24.57 | $261K |
| 2024-12-17 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 10.6K | $17.32 | $184K |
| 2024-12-17 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 10.6K | $3.85 | $41K |
| 2024-12-17 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 5.9K | $17.01 | $100K |
| 2024-12-17 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 5.9K | $3.85 | $23K |
Anderson Karen M. is a corporate insider — currently tracked as Chief People Officer of Centessa Pharmaceuticals plc (CNTA). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 9 open-market sales ($9.93M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Anderson Karen M. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.